Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Ramucirumab in Previously-Treated Mesothelioma
NCT03502746Phase 2Terminated
- Start
- Jun 2018
- Primary completion
- May 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ramucirumab in malignant mesothelioma. Primary endpoint: Response Rate at 23 months. Started Jun 2018; status: terminated.
02
Drugs
nivolumabramucirumab
03
Conditions
malignant mesothelioma
Beyond the preview
Go deeper on NCT03502746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03502746.